arrow
C

Colm Keane

Princess Alexandra Hospital
H指数:26
被引数:2,811

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase 1/2 study of favezelimab plus pembrolizumab in anti–PD-1–naive relapsed or refractory classical Hodgkin lymphoma

I期/II期研究:favezelimab联合pembrolizumab治疗抗PD-1初治复发或难治性经典型霍奇金淋巴瘤

2026-10-050
OAAI
PASTA: versatile tyramide-oligonucleotide amplification for multimodal spatial biology

PASTA:适用于多模态空间生物学的通用酪胺寡核苷酸扩增

2026-08-170
PRE
Meeting trial eligibility in Follicular lymphoma patients is associated with overall survival but not progression-free survival

滤泡性淋巴瘤患者满足临床试验入组标准与总生存期相关,但与无进展生存期无关。

2025-09-011
PRE
T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial

T细胞失调与B细胞淋巴瘤的放疗-免疫疗法反应:一项1期试验的结果

2025-06-260
OAAI
The 66th ASH Annual Meeting Abstracts

第66届ASH年会摘要

BLOOD
IF23.1
2024-11-050
PRE
Intra-tumoral and peripheral blood TIGIT and PD-1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma
2024-08-170
OAAI
Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study
2024-03-074
OAAI
Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia

免疫检查点抑制剂治疗慢性淋巴细胞白血病合并晚期黑色素瘤的疗效

2023-09-014
OA
Successful treatment of Epstein-Barr virus-associated primary central nervous system lymphoma due to post-transplantation lymphoproliferative disorder, with ibrutinib and third-party Epstein-Barr virus-specific T cells
2021-10-0116
OAAI